|
SECURITY: VAR (Common)
EXCHANGE: New York Stock Exchange CURRENCY: US Dollar
Varian Medical Systems is
today organized around three operations. Oncology Systems is the world's
largest supplier of integrated cancer equipment and systems, including
the market-leading Clinac medical linear accelerator. Its X-ray Tube Products
operation is the leading independent supplier of X-ray tubes for the worldwide
diagnostic imaging industry, including tubes expressly designed for the
most advanced mammography and computed tomography (CT) scanning applications.
Varian Medical Systems' Ginzton Technology Center has a mission to create,
acquire, and manage bold new breakthrough technologies that will further
advance medical diagnosis and treatment, while creating potentially high-growth
opportunities. The center's current focus is on brachytherapy, digital
X-ray imaging, and emerging biotechnologies.
Varian
Medical Systems Expects 12 Percent Net Orders Growth for Second Quarter
Fiscal 2007 with Softness in Oncology Systems and Strength in All Other
Businesses
PALO ALTO, Calif., April
12 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today announced
that it expects to report that total net orders in the second quarter of
fiscal year 2007, including orders generated in the quarter by the newly
acquired ACCEL Instruments business, grew by 12 percent over the year-ago
quarter to about $480 million with 2 percent growth in Oncology Systems
and strong growth in all other businesses.
"For the second quarter Oncology
Systems should have 19 percent growth in international orders and a 10
percent decline in North America -- an unpredicted reversal of what occurred
in the first quarter when we had strong North American business and delays
in international orders," said Tim Guertin, president and CEO of Varian
Medical Systems. "We are experiencing greater variability in the length
of our sales cycles caused by bigger deal sizes for more sophisticated
equipment and more complex customer decision processes."
Compared to the second quarter
of last year, net orders for the company's security and inspection business
are expected to rise by more than 225 percent, and Varian's X-Ray Products
business should have an estimated 16 percent increase in net orders, driven
largely by demand for flat panel image detectors for filmless X-ray imaging.
The company expects to report $22 million in net orders in the quarter
for proton therapy and instrumentation products received subsequent to
the ACCEL acquisition. Including consolidation of approximately $47 million
in acquired backlog from ACCEL, the company estimates total orders for
the second quarter should increase 23 percent and the quarter-ending backlog
should increase 19 percent from the year ago period.
Second quarter revenues,
including those from ACCEL, should increase by about 7 percent. "Excluding
ACCEL, revenues for the quarter were a couple of percentage points weaker
than expected due in part to construction delays at Oncology Systems customer
sites," Guertin said. "While we are disappointed at the slowness in Oncology
Systems for the first half of the fiscal year, it is gratifying to see
how much growth these emerging businesses can contribute to our company.
We remain confident in our long-term prospects, and we believe we can sustain
10 to 15 percent long-term growth for the company with contributions from
our emerging businesses," Guertin said.
"Earnings per diluted share
for the second quarter should be slightly ahead of previous guidance,"
Guertin said. The results provided in this release are preliminary numbers
and the company will provide more detailed information on Wednesday, April
25 when it reports the full results for the quarter.
Investor Conference Call
Today
Varian Medical Systems management
has scheduled a conference call for 3 p.m. PT today to respond to questions
related to this announcement. To hear a live webcast of the call, visit
the investor relations page on the company's web site at http://www.varian.com/.
To access the call via telephone, dial 1-800-573-4842 from inside the U.S.
or 1-617-224-4327 from outside the U.S. and enter confirmation code 17947003.
The replay can be accessed by dialing 1-888-286-8010 from inside the U.S.
or 1-617-801-6888 from outside the U.S. and entering confirmation code
76538805. The telephone replay will be available through 5 p.m. PT, Friday,
April 13, 2007. The replay will be archived on the company investor relations
website for up to a year.
Following the call, the company
will resume its quiet period until announcing the full results for the
second quarter at 1 p.m. PT on Wednesday, April 25, 2007 followed by the
management's regularly scheduled conference call at 2 p.m. PT. The April
25th call can be accessed via the company's website at http://www.varian.com/investor
or via telephone, by dialing 1-866-543-6408 from inside the U.S. or 1-617-213-8899
from outside the U.S. and enter confirmation code 99648622. The replay
can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888
from outside the U.S. and entering confirmation code 29487918. The telephone
replay will be available through 5 p.m. PT, April 27, 2007. The replay
will be archived and accessible on the company website for a year.
|